RG 7916

Drug Profile

RG 7916

Alternative Names: RG7916; RO 7034067

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator PTC Therapeutics
  • Developer PTC Therapeutics; Roche
  • Class
  • Mechanism of Action Survival of motor neuron 2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Spinal muscular atrophy

Most Recent Events

  • 01 Feb 2017 Hoffmann-La Roche plans a phase I trial in Healthy volunteers in USA (PO) (NCT03040635)
  • 24 Jan 2017 Hoffmann-La Roche plans the phase II Jewelfish trial for Spinal muscular atrophy (In adolescents, In adults, Treatment-experienced) in USA (PO) (NCT03032172)
  • 06 Jan 2017 RG 7916 receives Orphan Drug status for Spinal muscular atrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top